相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
N. Normanno et al.
ANNALS OF ONCOLOGY (2015)
Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer
Brigette B. Ma et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015)
A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
Akihito Kawazoe et al.
BMC CANCER (2015)
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers
Sally Temraz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
HER2/neu testing in primary colorectal carcinoma
B. Ingold Heppner et al.
BRITISH JOURNAL OF CANCER (2014)
A systematic review of dual targeting in HER2-positive breast cancer
Iben Kumler et al.
CANCER TREATMENT REVIEWS (2014)
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
Simonetta M. Leto et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2014)
Differential Features of Microsatellite-Unstable Colorectal Carcinomas Depending on EPCAM Expression Status
Jung Ho Kim et al.
Korean Journal of Pathology (2014)
Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
Yu Imamura et al.
MOLECULAR CANCER (2014)
HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression
An Na Seo et al.
PLOS ONE (2014)
Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer
Bun Kim et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
Sandra Misale et al.
CANCER DISCOVERY (2014)
HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
V. Martin et al.
BRITISH JOURNAL OF CANCER (2013)
Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis
Jens Neumann et al.
VIRCHOWS ARCHIV (2013)
Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature
Ibrahim Halil Sahin et al.
JOURNAL OF CANCER (2013)
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
C. Mao et al.
ANNALS OF ONCOLOGY (2012)
Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
Tomoya Yokota
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2012)
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
Mi-Jung Kim et al.
BMC CANCER (2012)
Microsatellite instability testing in Korean patients with colorectal cancer
Jung Ryul Oh et al.
FAMILIAL CANCER (2012)
Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma
Sung Lee et al.
VIRCHOWS ARCHIV (2012)
Targeting PI3K Signaling as a Therapeutic Approach for Colorectal Cancer
Jing Zhang et al.
GASTROENTEROLOGY (2011)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
Emma R. Cantwell-Dorris et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
Stephan E. Baldus et al.
CLINICAL CANCER RESEARCH (2010)
The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Genetic prognostic and predictive markers in colorectal cancer
Axel Walther et al.
NATURE REVIEWS CANCER (2009)
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program
J. H. J. M. van Krieken et al.
VIRCHOWS ARCHIV (2008)
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
C. Oliveira et al.
ONCOGENE (2007)
分享论文
